uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

ByLois C

May 10, 2022 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
uniQure Inc.

uniQure Inc.

LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (Globe NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a top gene remedy enterprise advancing transformative therapies for individuals with severe health care requirements, now announced that six data displays, like just one oral presentation, will be delivered at the American Society of Gene and Cell Treatment (ASGCT) Hybrid Congress 2022 Yearly Conference getting held May perhaps 16-19 in Washington, D.C.

“Our displays at ASGCT showcase the exceptional work of our uniQure scientists and the breadth of our investigation pipeline as we progress our investigational AAV gene remedy programs,” said Ricardo Dolmetsch, Ph.D. president of analysis and enhancement at uniQure. “We are notably proud of our experiments demonstrating the prospective of the linQURE® cargo platform, providing numerous miRNAs in a solitary AAV and its software to selectively silence mutant C9orf72 in an ALS preclinical model.”

Specific specifics on uniQure’s displays having location at ASGCT include:

  • Title: Alpha-synuclein lowering and rescue of motor phenotype by miRNA-centered AAV gene treatment in in vivo Parkinson’s ailment designs (Summary #19)
    Presenter: Astrid Valles-Sanchez, Ph.D. director of CNS ailment biology, uniQure
    Oral Session Title: Oligonucleotide Therapeutics
    Date and Time: Monday, May 16, 11:15 – 11:30 a.m. EDT

  • Title: Construction and optimization of novel adeno-linked virus (AAV) rep gene expression command procedure for stable rAAV-packaging insect mobile line (Abstract #407)
    Poster Session Title: Vector Solution Engineering, Improvement or Manufacturing I
    Session Day and Time: Monday, May well 16, 5:30 – 6:30 p.m. EDT

  • Title: Useful transfer of engineered microRNAs through extracellular vesicles: An in vitro proof-of-mechanism study in Huntington’s condition styles (Abstract #590)
    Poster Session Title: Oligonucleotide Therapeutics II
    Session Day and Time: Tuesday, Could 17, 5:30 – 6:30 p.m. EDT

  • Title: Selective silencing of mutant C9orf72 transcripts (Summary #552)
    Poster Session Title: Gene Focusing on and Gene Correction II
    Date and Time: Tuesday, May 17, 5:30 – 6:30 p.m. EDT

  • Title: AAV5-GLA gene therapy effects in sustained prolonged expression GLA transgene expression and cross correction of target organs in Fabry disorder mouse design (Summary #1009)
    Poster Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases II
    Session Day and Time: Wednesday, Might 18, 5:30 p.m. EDT

  • Title: AAV-mediated APOE gene silencing for Alzheimer’s disorder (Summary #918)
    Poster Session Title: AAV Vectors – Preclinical and Evidence-of-principle Scientific studies III
    Date and Time: Wednesday, May 18, 5:30 p.m. EDT

About uniQure
uniQure is providing on the guarantee of gene treatment – one treatments with perhaps curative success. We are leveraging our modular and validated technological innovation system to speedily advance a pipeline of proprietary gene therapies to address clients with hemophilia B, Huntington’s disorder, refractory temporal lobe epilepsy, Fabry disorder, and other ailments. www.uniQure.com

uniQure Contacts:

By Lois C